The Mouse Was Cured 
The Patient Wasn't

Hello, I’m Åsa Johansson. CEO at Offspring Biosciences.

​

If you’re reading this, then hopefully you had the chance to connect with one of our extraordinary senior experts, Dan and Anders, at AD/PD, and wanted to learn more about what we do.

 

At Offspring, we help bridge the translational gap and de-risk antibody development by validating candidates in the only environment that truly predicts clinical success: human disease tissue.

 

Nearly 90% of antibody candidates that look promising in preclinical and animal models ultimately fail in human trials. The Translational Gap thrives on a lack of early human validation.

 

Our Tissue-Insights™ platform combines advanced histopathology, quantitative digital imaging, AI-driven analysis and decades of human experience to move beyond subjective scoring, answering not just whether a drug binds — but where it binds, how it behaves in context, and whether that interaction is likely to matter.  We turn pixels into statistically grounded, decision-ready data — providing meaningful go/no-go confidence before the clinic.

 

We’re proud to have generated key human tissue data supporting successful advancement of multiple AD/PD therapeutics — demonstrating selective binding in real patient brain tissue. That experience informs every project we take on."

 

If this approach resonates with your current program, if you simply have questions about human tissue validation, or if you just LOVE to discuss your science with someone just as interested, we invite you to use the contact form below to schedule a follow-up discussion with one of our senior scientists.

 

We look forward to continuing our conversation and seeing how Offspring Biosciences can help your project successfully bridge the Translational Gap and to not just succeed, but thrive in the Clinic and beyond.